UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOW - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2025	Sep. 30, 2024
CASH FLOWS FROM OPERATING ACTIVITIES
Net income	$ 8,720	$ 10,972
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation	614	530
Amortization	1,593	1,548
Provision for (recovery of) losses on accounts receivable	395	(6)
Amortization of right of use assets	41	38
Deferred income taxes	(641)	(417)
Stock-based compensation expense	262	184
Tax benefit attributable to exercise of stock options	0	20
Accounts receivable and other receivables	(97)	(306)
Inventories	1,009	508
Prepaid expenses and other current assets	52	54
Accounts payable	69	229
Accrued expenses	(802)	(1,460)
Total adjustments	2,495	922
Net cash provided by operating activities	11,215	11,894
CASH FLOWS FROM INVESTING ACTIVITIES
Property and equipment	(262)	(221)
Intangible assets	0	(5)
Property and equipment	0	27
Net cash used in investing activities	(262)	(199)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from issuance of common stock - options	0	390
Common stock purchased and retired	(7,361)	(13,259)
Payment of dividends	(3,006)	(3,222)
Net cash used in financing activities	(10,367)	(16,091)
Effect of exchange rate changes on cash	705	(20)
Net increase/(decrease) in cash and cash equivalents	1,291	(4,416)
Cash at beginning of period	82,976	92,868
Cash at end of period	84,267	88,452
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION
Cash paid during the period for income taxes	2,852	3,713
Cash paid during the period for interest	$ 0	$ 0